GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Cash And Cash Equivalents

MedMira (MedMira) Cash And Cash Equivalents : $0.64 Mil (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Cash And Cash Equivalents?

MedMira's quarterly cash and cash equivalents increased from Jul. 2023 ($0.01 Mil) to Oct. 2023 ($0.65 Mil) but then stayed the same from Oct. 2023 ($0.65 Mil) to Jan. 2024 ($0.64 Mil).

MedMira's annual cash and cash equivalents increased from Jul. 2021 ($0.00 Mil) to Jul. 2022 ($0.03 Mil) but then declined from Jul. 2022 ($0.03 Mil) to Jul. 2023 ($0.01 Mil).


MedMira Cash And Cash Equivalents Historical Data

The historical data trend for MedMira's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Cash And Cash Equivalents Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.30 - 0.03 0.01

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.06 0.01 0.65 0.64

MedMira Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


MedMira  (OTCPK:MMIRF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


MedMira Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of MedMira's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022

MedMira Reports First Quarter Results FY2023

By ACCESSWIRE ACCESSWIRE 12-31-2022

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018